Simon Spazzapan

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

Prudence A. Francis, Olivia Pagani, Gini F. Fleming et al. · New England Journal of Medicine · 2018 · 646 citations · Full text

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

Jesse J. Swen, Cathelijne H. van der Wouden, Lisanne E. N. Manson et al. · The Lancet · 2023 · 462 citations · Full text

Drug Safety, Adverse Drug Reactions, Pharmacoepidemiology +9

Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials

Jürg Bernhard, Weixiu Luo, Karin Ribi et al. · The Lancet Oncology · 2015 · 172 citations · Full text

Patient-reported Outcomes, Breast Oncology, Phase 3 +13

Radical radiation therapy for oligometastatic breast cancer: Results of a prospective phase II trial

Marco Trovò, Carlo Furlan, Jerry Polesel et al. · Radiotherapy and Oncology · 2017 · 163 citations

Radiation Medicine, Surgical Oncology, Health Sciences +9

Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials

Olivia Pagani, Barbara Walley, Gini F. Fleming et al. · Journal of Clinical Oncology · 2022 · 141 citations · Full text